CellF Bio

Cellf BIO LLC is an early-stage regenerative stem cell tissue bioengineering company founded in 2014. Cellf BIO envisions pioneering regenerative medicine-based therapies for common functional digestive disorders and neurodegenerative diseases of the GI tract. Cellf BIO maintains patent protection for critical platform technologies and processes. These technologies also enable Cellf BIO to pursue additional products for urinary incontinence (UI) and esophageal reconstruction.

INDUSTRY LANDSCAPE: Colorectal surgery; Neurodegenerative disease; Tissue Engineering; Stem Cells.

TECHNOLOGY: The BioSphincterTM is a patent-protected technology. The BioSphincterTM is bioengineered from smooth muscle cells and stem cells, retrieved in a biopsy procedure from the patient’s own cells (eliminating rejection risk). The newly grown autologous sphincter is implanted over the defective sphincter, becoming a new continuum of the gut, which reconnects with the local neural reflexes in the area.

MARKET NEED: Fecal incontinence (FI) is the inability to control your bowel movements, causing stool (feces) to leak unexpectedly from the rectum. It is a problem faced by 1 in 12 people, or 18 million adults, in the US. FI affects all aspects of peoples’ lives, greatly reducing the quality of physical and mental health.

MILESTONES • IND/FDA clearance to proceed to phase 1 clinical trials June 2022 • start Clinical Phase 1 Trial enrolling patients.